Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cadonilimab,AK109,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Akeso
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CDE Approval for AK104 (Cadonilimab) with Ivonescimab is on the basis of clinical trial data, which showed significantly better results than CTLA-4 inhibitors in the market and, it is expected to refresh the new efficacy record in the current field of NS...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 01, 2022
Lead Product(s) : Cadonilimab,AK109,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Akeso
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Potassium Citrate
Therapeutic Area : Urology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 02, 2017
Lead Product(s) : Potassium Citrate
Therapeutic Area : Urology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
